Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

  • Post published:August 25, 2022
  • Post category:Press Release
Read more about the article MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

  • Post published:April 14, 2022
  • Post category:Press Release
Read more about the article MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

  • Post published:April 5, 2022
  • Post category:Press Release
Read more about the article MindMed Reports Full Year 2021 Financial Results and Business Highlights

MindMed Reports Full Year 2021 Financial Results and Business Highlights

  • Post published:March 28, 2022
  • Post category:Press Release
Read more about the article MindMed Announces Transition of CFO

MindMed Announces Transition of CFO

  • Post published:March 25, 2022
  • Post category:Press Release
Read more about the article MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

  • Post published:February 23, 2022
  • Post category:Press Release
Read more about the article FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

  • Post published:January 25, 2022
  • Post category:Press Release
Read more about the article MindMed Enrolls First Participant in a Study of its Session Monitoring System

MindMed Enrolls First Participant in a Study of its Session Monitoring System

  • Post published:January 18, 2022
  • Post category:Press Release
Read more about the article Stephen Hurst Resigns from MindMed Board of Directors

Stephen Hurst Resigns from MindMed Board of Directors

  • Post published:January 7, 2022
  • Post category:Press Release
Read more about the article MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

  • Post published:January 4, 2022
  • Post category:Press Release

End of content

No more pages to load

Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More